State Street Lags Its Peers as Short Sellers Stay Put

STT fell 0.7% over the past week, while the median of its closest custody and asset-management peers gained around 0.4%. BNY added 1.2% and NTRS rose 1.3%, leaving State Street the clearest underperformer in the group.

Short positioning at STT is lighter than the peer group picture might suggest. Shares short edged down slightly on the week to 6.3 million, equivalent to 2.3% of the free float, and cost to borrow is negligible at 0.34%. Availability has actually loosened further, reaching roughly 9,451%, meaning the pool of shares available to lend dwarfs the amount currently lent out by nearly a hundredfold. The ORTEX short score of 33.8 places the stock comfortably in the middle of the coverage universe, unchanged in direction from last week. The previous note flagged a sharp 21% weekly jump in short interest; that build has now stalled, with shares short essentially flat across the past five sessions. The story this week is less about an active short campaign and more about a stock that is drifting without a clear catalyst, while peers find firmer footing.

The analyst picture is mixed but tilted toward caution following October's earnings print. Most firms held their ratings but trimmed targets in the two weeks after the Q3 release. The exception was Keefe Bruyette, which raised its target to $230 from $220 while maintaining Outperform, the most bullish call on the board. JP Morgan, maintaining Neutral, lifted its target modestly to $192.50 last week, the most recent action on the stock. The mean consensus target is $192.63, implying about 13% from the current price of $169.71. The bull case rests on record assets under custody of $59.17 trillion, 25.1% ROTCE in Q3, and management's raised fee and NII guidance for 2026. The bear case is about execution: servicing, FX and other fees have missed in recent quarters, pricing power is limited, and the Alpha platform and private markets buildout have yet to shift the revenue mix in a meaningful way. The PE multiple has contracted 0.6 points over the past month to 11.1x, with price-to-book at 1.72x, neither cheap enough to be a screaming value nor expensive enough to attract fresh shorts. The analyst recommendation divergence score ranks in the 92nd percentile, reflecting genuine disagreement on whether the valuation discount to peers is justified or a value trap.

Insider flow adds a small signal in the same direction as the share price weakness. CEO Ronald O'Hanley sold 14,554 shares on October 20 for approximately $2.4 million, and Chief Risk Officer Bradford Hu sold 7,099 shares on October 26 for roughly $1.2 million. Both trades were conducted under pre-arranged 10b5-1 plans, which limits their informational weight considerably. No open-market purchases appear in the recent record. Net insider sales over the past 90 days total around $3.7 million. On its own this is not alarming, scheduled plan sales by senior executives are routine, but there is no offsetting buy-side conviction from insiders at current levels.

The FDIC call reports for State Street's insured bank charters show quarterly net income up 60% on the same quarter a year earlier, with net loans and leases rising for three consecutive quarters. ORTEX has not yet established whether the FDIC data leads the company's reported figures, so these numbers are colour rather than a forward read on the January print. What they do confirm is that the deposit and lending book has been performing well through mid-2026, consistent with the NII resilience the company cited in its Q3 results.

The next earnings event is 15 January 2027. The past two Q3 and Q2 prints both produced negative one-day reactions of roughly 3.7% and 2.2% respectively, so the market's recent pattern has been to sell the news even when results are not obviously weak. The level to watch on positioning is whether short interest moves back above 6.3 million shares, the point at which last week's acceleration stalled, or whether the stock can recapture the gap to peers before the January release.